Silexion Therapeutics Corp. (SLXN) stock surged over 21% in pre-market trading following the release of promising Phase 2 trial data for its first-generation product, LODER. The updated analysis revealed a significant objective response rate (ORR) in patients with pancreatic cancer, highlighting LODER’s potential to improve treatment outcomes and increase the resectability of tumors.